Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

LIGAND PHARMACEUTICALS INC

LGND · Nasdaq; OTC · CIK 0000886163 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

92 Form 4 transaction lines observed in the same window
62 sales · 30 option, withholding, award, gift or other lines

Last qualifying purchase2025-05-09 · Davis Todd C · $1.0M

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesHigh
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Reardon AndrewCLO & Secretary
○▼○▼○○▼○▼▼○▼
KOZARICH JOHN WDirector
▼○▼○▼○
Haas JasonDirector
○○▼○▼
Zimmermann MartineDirector
○○▼○
Espinoza OctavioChief Financial Officer
○○○▼
Sabba Stephen LDirector
○○▼
● Purchase▼ Sale○ Other

Showing the six most active owners; 4 additional owner(s) remain in Form 4 evidence.

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2025-05-09 · Davis Todd C.

Recent Form 4 activity

0Purchases
131Sales
74Other Form 4 lines
51SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING62 sale line(s) · context only
OTHER30 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
2,677,998
Previous report
2,632,434
Avg daily volume
306,650
Days to cover
8.7

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2025-05-09Espinoza OctavioPurchase (P)Common Stock1,500USD 104.06USD 156,090SEC filing ↗
2025-05-09Davis Todd CPurchase (P)Common Stock9,510USD 105.20USD 1,000,444SEC filing ↗
2024-08-08Davis Todd CPurchase (P)Common Stock2,500USD 97.39USD 243,475SEC filing ↗
2023-09-22Davis Todd CPurchase (P)Common Stock4,000USD 59.38USD 237,520SEC filing ↗
2022-05-13FOEHR MATTHEW WPurchase (P)Common Stock2,500USD 82.76USD 206,900SEC filing ↗
2020-11-02Patel SunilPurchase (P)Common Stock1,000USD 82.52USD 82,520SEC filing ↗

Form 4 evidence

205 transaction lines in the latest 365-day window; 573 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-02Reardon AndrewSale (S)Common Stock5,000USD 304.07USD 1,520,346SEC filing ↗
2026-10-02Reardon AndrewOption exercise / conversion (M)Common Stock340USD 52.27USD 17,772SEC filing ↗
2026-09-22Zimmermann MartineTax withholding (F)Common Stock115USD 298.50USD 34,328SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-02Reardon AndrewSale (S)Common Stock5,000USD 304.07USD 1,520,346SEC filing ↗
2026-10-02Reardon AndrewOption exercise / conversion (M)Common Stock340USD 52.27USD 17,772SEC filing ↗
2026-09-22Zimmermann MartineTax withholding (F)Common Stock115USD 298.50USD 34,328SEC filing ↗
2026-09-10Zimmermann MartineSale (S)Common Stock1,200USD 285.00USD 342,000SEC filing ↗
2026-09-03Reardon AndrewSale (S)Common Stock5,000USD 286.09USD 1,430,445SEC filing ↗
2026-08-12Haas JasonSale (S)Common Stock7,138USD 292.81USD 2,090,078SEC filing ↗
2026-08-12Haas JasonOption exercise / conversion (M)Common Stock6,138USD 51.56USD 316,475SEC filing ↗
2026-08-12Espinoza OctavioSale (S)Common Stock31,641USD 292.07USD 9,241,387SEC filing ↗
2026-08-12Espinoza OctavioOption exercise / conversion (M)Common Stock31,641USD 56.91USD 1,800,574SEC filing ↗
2026-08-03Reardon AndrewSale (S)Common Stock5,000USD 288.99USD 1,444,949SEC filing ↗
2026-08-03Reardon AndrewOption exercise / conversion (M)Common Stock5,000USD 52.27USD 261,350SEC filing ↗
2026-07-01Reardon AndrewSale (S)Common Stock5,000USD 313.28USD 1,566,382SEC filing ↗
2026-07-01Reardon AndrewOption exercise / conversion (M)Common Stock5,000USD 52.27USD 261,350SEC filing ↗
2026-06-30Reardon AndrewJ (J)Common Stock132USD 160.71USD 21,214SEC filing ↗
2026-06-30Espinoza OctavioJ (J)Common Stock17USD 160.71USD 2,732SEC filing ↗
2026-06-30Davis Todd CJ (J)Common Stock132USD 160.71USD 21,214SEC filing ↗
2026-06-16Sabba Stephen LSale (S)Common Stock2,145USD 254.00USD 544,830SEC filing ↗
2026-06-16Sabba Stephen LOption exercise / conversion (M)Common Stock2,145USD 66.13USD 141,849SEC filing ↗
2026-06-12Haas JasonSale (S)Common Stock6,461USD 255.58USD 1,651,323SEC filing ↗
2026-06-12Haas JasonOption exercise / conversion (M)Common Stock4,000USD 51.56USD 206,240SEC filing ↗
2026-06-11Aryeh JasonSale (S)Common Stock4,500USD 250.00USD 1,125,000SEC filing ↗
2026-06-10LAMATTINA JOHN LSale (S)Common Stock4,591USD 250.88USD 1,151,786SEC filing ↗
2026-06-10Aryeh JasonSale (S)Common Stock500USD 250.00USD 125,000SEC filing ↗
2026-06-05Aryeh JasonAward / grant (A)Common Stock836USD 0.00USD 0SEC filing ↗
2026-06-05Zimmermann MartineTax withholding (F)Common Stock182USD 237.00USD 43,134SEC filing ↗
2026-06-05Zimmermann MartineAward / grant (A)Common Stock836USD 0.00USD 0SEC filing ↗
2026-06-05Sabba Stephen LAward / grant (A)Common Stock836USD 0.00USD 0SEC filing ↗
2026-06-05LAMATTINA JOHN LAward / grant (A)Common Stock836USD 0.00USD 0SEC filing ↗
2026-06-05KOZARICH JOHN WAward / grant (A)Common Stock836USD 0.00USD 0SEC filing ↗
2026-06-05Haas JasonAward / grant (A)Common Stock836USD 0.00USD 0SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerLGND
CIK0000886163
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq; OTC

Data coverage

Local Form 4 history573 transaction lines from 2020-02-13 to 2026-10-02
9 P purchase lines · 204 S sale lines · 360 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.